---
figid: PMC7912509__13148_2021_1021_Fig1_HTML
figlink: pmc/articles/PMC7912509/figure/Fig1/
number: Fig. 1
caption: Selected mechanisms of action of SMYD3 as an oncogenic driver. a Histone-mediated
  mechanisms. (i) SMYD3 tri-methylates H3K4, with HSP90A enhancing its enzymatic activity.
  (ii) SMYD3 tri-methylates H4K20. In ovarian cancer cells, CDKN2A is repressed via
  SMYD3-mediated H4K20 tri-methylation. b Non-Histone-mediated mechanisms. (i) SMYD3
  methylates vascular endothelial growth factor receptor 1 (VEGFR1) at lysine 831
  and enhances its kinase activity. (ii) SMYD3 methylates mitogen-activated protein
  kinase kinase kinase 2 (MAP3K2) at lysine 260, preventing its dephosphorylation
  by protein phosphatase 2 (PP2A) and activating the MAP kinase pathway. (iii) SMYD3
  methylates v-Akt murine thymoma viral oncogene homolog 1 (AKT1) at lysine 14 and
  increases its phosphorylation and activation. (iv) SMYD3 acts as a co-activator
  of the estrogen receptor (ER), increasing the transcription of ER-mediated downstream
  genes. (v) SMYD3 methylates human epidermal growth factor receptor 2 (HER2) at lysine
  175, enhancing HER2 homodimerization and autophosphorylation
pmcid: PMC7912509
papertitle: 'SMYD3: a regulator of epigenetic and signaling pathways in cancer.'
reftext: Benjamin J. Bernard, et al. Clin Epigenetics. 2021;13:45.
pmc_ranked_result_index: '51619'
pathway_score: 0.7735973
filename: 13148_2021_1021_Fig1_HTML.jpg
figtitle: Selected mechanisms of action of SMYD3 as an oncogenic driver
year: '2021'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7912509__13148_2021_1021_Fig1_HTML.html
  '@type': Dataset
  description: Selected mechanisms of action of SMYD3 as an oncogenic driver. a Histone-mediated
    mechanisms. (i) SMYD3 tri-methylates H3K4, with HSP90A enhancing its enzymatic
    activity. (ii) SMYD3 tri-methylates H4K20. In ovarian cancer cells, CDKN2A is
    repressed via SMYD3-mediated H4K20 tri-methylation. b Non-Histone-mediated mechanisms.
    (i) SMYD3 methylates vascular endothelial growth factor receptor 1 (VEGFR1) at
    lysine 831 and enhances its kinase activity. (ii) SMYD3 methylates mitogen-activated
    protein kinase kinase kinase 2 (MAP3K2) at lysine 260, preventing its dephosphorylation
    by protein phosphatase 2 (PP2A) and activating the MAP kinase pathway. (iii) SMYD3
    methylates v-Akt murine thymoma viral oncogene homolog 1 (AKT1) at lysine 14 and
    increases its phosphorylation and activation. (iv) SMYD3 acts as a co-activator
    of the estrogen receptor (ER), increasing the transcription of ER-mediated downstream
    genes. (v) SMYD3 methylates human epidermal growth factor receptor 2 (HER2) at
    lysine 175, enhancing HER2 homodimerization and autophosphorylation
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CHRDL1
  - FLT1
  - SMYD3
  - LYST
  - AKT2
  - AKT3
  - AKT1
  - ERBB2
  - CHI
  - CHD
genes:
- word: CHI
  symbol: CHL
  source: hgnc_alias_symbol
  hgnc_symbol: CHRDL1
  entrez: '91851'
- word: VEGFR1
  symbol: VEGFR1
  source: hgnc_alias_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: SMYD3
  symbol: SMYD3
  source: hgnc_symbol
  hgnc_symbol: SMYD3
  entrez: '64754'
- word: CHI
  symbol: CHL
  source: hgnc_alias_symbol
  hgnc_symbol: CHRDL1
  entrez: '91851'
- word: CHS
  symbol: CHS
  source: hgnc_alias_symbol
  hgnc_symbol: LYST
  entrez: '1130'
- word: SMYD3
  symbol: SMYD3
  source: hgnc_symbol
  hgnc_symbol: SMYD3
  entrez: '64754'
- word: CHI
  symbol: CHL
  source: hgnc_alias_symbol
  hgnc_symbol: CHRDL1
  entrez: '91851'
- word: CHI
  symbol: CHL
  source: hgnc_alias_symbol
  hgnc_symbol: CHRDL1
  entrez: '91851'
- word: CHI
  symbol: CHL
  source: hgnc_alias_symbol
  hgnc_symbol: CHRDL1
  entrez: '91851'
- word: SMYD3
  symbol: SMYD3
  source: hgnc_symbol
  hgnc_symbol: SMYD3
  entrez: '64754'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: CHI
  symbol: CHL
  source: hgnc_alias_symbol
  hgnc_symbol: CHRDL1
  entrez: '91851'
- word: CHS
  symbol: CHS
  source: hgnc_alias_symbol
  hgnc_symbol: LYST
  entrez: '1130'
- word: SMYD3
  symbol: SMYD3
  source: hgnc_symbol
  hgnc_symbol: SMYD3
  entrez: '64754'
- word: SMYD3
  symbol: SMYD3
  source: hgnc_symbol
  hgnc_symbol: SMYD3
  entrez: '64754'
- word: SMYD3
  symbol: SMYD3
  source: hgnc_symbol
  hgnc_symbol: SMYD3
  entrez: '64754'
- word: HER2
  symbol: HER2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: HER2
  symbol: HER2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: HER2
  symbol: HER2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: HER2
  symbol: HER2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: HER2
  symbol: HER2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
chemicals:
- word: CHI
  source: MESH
  identifier: C084533
diseases:
- word: CHD
  source: ''
  identifier: ''
---
